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The present study investigated the mechanism by which eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) 
inhibit platelet activation i duced by thromboxane ,%. DHA was found to be more potent than EPA in blocking platelet 
aggregation i duced by the stable thromboxane A z mimetic, U46619. Furthermore, this inhibition by DHA or EPA was 
competitive. Binding studies using 3H-U46619 demonstrated that both EPA and DHA interact with the platelet throm- 
boxane receptor. The potency of the inhibition of binding corresponded with that seen for the inhibition of aggregation. 
These results uggest that thromboxane r ceptor antagonism ay be an important mechanism by which EPA and DHA 
modulate platelet reactivity in vivo. 
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1. INTRODUCTION 
Epidemiological  studies uggest hat populat ions 
whose diet contains increased amounts of  seafood 
have a decreased incidence o f  occlusive vascular 
disease [1,2]. A possible basis for such a preventive 
effect could be an inhibit ion of  b lood platelet in- 
volvement in thrombosis  by the marine fatty acids 
e icosapentaenoic a id (EPA)  and docosahexaenoic 
acid (DHA) .  Since thromboxane is considered to 
be an important  vector in the genesis of  throm- 
boembol ic  disorders [3], mar ine fatty acid inhibi- 
t ion of  thromboxane-mediated platelet aggrega- 
t ion may in part  explain the reduct ion in the in- 
cidence of  occlusive vascular disease. Support  for 
this idea has come from in vitro studies which have 
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shown that EPA and DHA inhibit platelet activa- 
t ion induced by thromboxane analogs like U46619 
[4-6] .  Whi le EPA and DHA are known to inhibit 
cyclo-oxygenase [7], inhibit ion of  U46619-me- 
d iated platelet act ivat ion would suggest hat EPA 
and DHA may also act as thromboxane receptor 
antagonists.  Based on these considerat ions,  we in- 
vestigated the abi l i ty of  EPA and DHA to directly 
interact at the level of  the platelet thromboxane 
receptor.  
2. MATERIALS  AND METHODS 
Human platelet-rich plasma was obtained from LifeSource 
Blood Services (Chicago). Free fatty acids were purchased from 
either Sigma (St. Louis) or Cayman Chemical (Ann Arbor). 
Platelets were isolated as previously described [8] with the ex- 
ception that 10 mM Hepes was substituted for 25 mM Tris. 
Platelet aggregation was measured by a turbidometric pro- 
cedure [9]. Fatty acid or ethanol (final ethanol concentration 
was 0.1070) was added to platelets (approx. 90 s before aggrega- 
tion was induced) followed by fibrinogen (100/~g/ml) and 
CaCl2 (100/zM). The measurement of the specific binding of 
3H-U46619 (22.4 Ci/mmol, gift of Dr E. Do, New England 
Nuclear, Boston, MA) to washed human platelets was as 
previously described [10]. 
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3. RESULTS 
Initially, the relative ability of EPA and DHA to 
inhibit platelet aggregation i duced by U46619 was 
quantitated. It was found that both EPA and 
DHA inhibited U46619-induced platelet aggrega- 
tion in a dose-dependent manner with DHA more 
potent than EPA (fig.l). The concentration of 
EPA necessary for 50% inhibition (ICso) was 5.9 + 
0.8/~M (n = 3) while the ICso for DHA was 2.2 + 
0.6/zM (n = 4). A saturated fatty acid, eicosanoic 
acid (20:0, EA), had little effect on aggregation 
(fig.l). 
We next determined whether the observed in- 
hibition of aggregation was competitive or non- 
competitive. The extent of aggregation was plotted 
as a function of the dose of U46619, and these 
dose-response curves were constructed in the 
absence and presence of various doses of EPA or 
DHA. These data were transformed by the method 
of Arunlakshana nd Schild [11]. This analysis 
revealed slopes not significantly different from one 
suggesting that DHA and EPA are competitive in- 
hibitors of U46619-induced aggregation atthe level 
of the thromboxane receptor (fig.2). Thrombox- 
ane receptor antagonism was further evaluated by 
performing direct binding studies using radio- 
labeled U46619. 
EPA and DHA both inhibited specific binding 
of 3H-U46619 in a dose-dependent manner (fig.3). 
Again, DHA was more potent (IC5o = 1.5 _+ 
0.22/zM; n = 4) than EPA (ICso = 5.6 + 1.02/zM; 
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Fig.1. Inhibition of U46619-induced platelet aggregation by 
DHA (circles), EPA (diamonds) and EA (triangles). The dose 
of U46619 was that which just caused maximal aggregation and 
varied between 40 and 160 nM. 
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Fig.2. Schild transformation of DHA (circles) and EPA 
(diamonds) effects on U46619 induced-aggregation dose- 
response curves. Individual plot slopes were - 1.01 + 0.099 for 
DHA and - 1.13 + 0.255 for EPA. 
n = 5). These IC5o values for inhibition of binding 
are not significantly different from the ICso values 
seen for inhibition of aggregation. Hence, a large 
part of the functional inhibition can be explained 
by the inhibition of receptor binding. Again, the 
saturated fatty acid, eicosanoic acid (EA), had lit- 
tle effect on binding. 
In order to determine whether the observed in- 
hibition of 3H-U46619 binding by EPA and DHA 
was due to cyclo-oxygenase [12] or lipoxygenase 
[13] products, additional binding studies were per- 
formed in the presence of the cyclo-oxygenase in-
hibitor indomethacin or the lipoxygenase inhibitor 
BW755c. We observed that neither indomethacin 
nor BW755c significantly reduced the inhibitory 
potency of EPA or DHA demonstrating that the 
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Inhibition of specific 3H-U46619 binding by DHA 
(circles), EPA (diamonds), and EA (triangles). 
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parent fatty acids are responsible for the observed 
effect (not shown). 
4. DISCUSSION 
The present studies demonstrate that the un- 
saturated fatty acids DHA and EPA inhibit 
U46619-induced platelet aggregation in a com- 
petitive manner and block the interaction of 3H- 
U46619 with the platelet thromboxane receptor. 
One possible explanation for the observed inhibi- 
tion of aggregation is that unsaturated fatty acids 
cause a generalized membrane perturbation such 
as an increase in membrane fluidity [14,15]. 
However, not all studies have been able to show an 
association between increased membrane fluidity 
and inhibition of platelet aggregation [16]. Fur- 
thermore, a generalized membrane perturbation 
would not seem to explain the unique effects EPA 
and DHA have on thromboxane-mediated platelet 
activation. For example, EPA is more effective in 
inhibiting U46619-induced platelet aggregation 
than aggregation i duced by other agonists [4]. In 
addition, the competitive nature of the functional 
inhibition as revealed by Schild analysis uggests a 
direct interaction of EPA and DHA with the 
platelet thromboxane receptor. These arguments 
do not exclude the possibility that at higher doses 
and with other platelet aggregating agents, the in- 
hibitory action of unsaturated fatty acid is based 
on the ability to increase membrane fluidity. 
However, the data do suggest hat there is a par- 
ticular sensitivity of thromboxane-mediated 
platelet activation to the presence of unsaturated 
fatty acids like EPA and DHA. 
In conclusion, EPA and DHA are capable of 
directly inhibiting agonist interaction with the 
thromboxane r ceptor. This inhibition of binding 
is presumably responsible for a major portion of 
the functional effects of these fatty acids on 
thromboxane-mediated platelet activation and 
may serve as a mechanism for their anti- 
thrombotic effects. 
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